Analyst Whitney Ijem from Canaccord Genuity maintained a Sell rating on Vertex Pharmaceuticals (VRTX – Research Report) and decreased the price target to $361.00 from $376.00. Whitney Ijem has ...

As of October 28, 2024, Vertex Pharmaceuticals Incorporated had a $123.0 billion market capitalization, putting it in the 98th percentile of companies in the Biotechnology industry. Vertex ...

Vertex Pharmaceuticals is in the process of getting a new painkiller approved. It just published some data that suggests the candidate will be quite profitable. But regulators still need to sign ...

Scotiabank has recently initiated Vertex Pharmaceuticals Incorporated (VRTX) stock to Sector Perform rating, as announced on October 16, 2024, according to Finviz. Earlier, on October 10, 2024, ...

Considering these conducive trends, let’s take a look at the fundamentals of the three pharma picks. Vertex Pharmaceuticals Incorporated (VRTX) VRTX is a biotechnology company that develops and ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $478.09, reflecting a -1.02% shift from the previouse trading day's closing. This change lagged the S&P 500's 0 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Deep-pocketed investors have adopted a bullish approach towards Vertex Pharmaceuticals VRTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

VRTX will need to target hospitals and surgical centers as well as physicians' offices. Marketing will involve working with hospitals to gain formulary access through the Pharmacy & Therapeutics ...